- Home
- RZLT vs CGEN Comparison
RZLT vs CGEN Comparison
Compare RZLT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RZLT
- CGEN
- Stock Information
- Founded
- RZLT 2010
- CGEN 1993
- Country
- RZLT United States
- CGEN Israel
- Employees
- RZLT N/A
- CGEN N/A
- Industry
- RZLT Biotechnology: Pharmaceutical Preparations
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RZLT Health Care
- CGEN Health Care
- Exchange
- RZLT Nasdaq
- CGEN Nasdaq
- Market Cap
- RZLT 361.3M
- CGEN 167.4M
- IPO Year
- RZLT N/A
- CGEN 2000
- Fundamental
- Price
- RZLT $5.11
- CGEN $1.58
- Analyst Decision
- RZLT Strong Buy
- CGEN
- Analyst Count
- RZLT 6
- CGEN 0
- Target Price
- RZLT $12.00
- CGEN N/A
- AVG Volume (30 Days)
- RZLT 1.5M
- CGEN 154.0K
- Earning Date
- RZLT 05-13-2025
- CGEN 08-05-2025
- Dividend Yield
- RZLT N/A
- CGEN N/A
- EPS Growth
- RZLT N/A
- CGEN N/A
- EPS
- RZLT N/A
- CGEN N/A
- Revenue
- RZLT N/A
- CGEN $27,589,000.00
- Revenue This Year
- RZLT $35.39
- CGEN N/A
- Revenue Next Year
- RZLT N/A
- CGEN $105.77
- P/E Ratio
- RZLT N/A
- CGEN N/A
- Revenue Growth
- RZLT N/A
- CGEN N/A
- 52 Week Low
- RZLT $2.22
- CGEN $1.13
- 52 Week High
- RZLT $6.19
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- RZLT 65.73
- CGEN 43.53
- Support Level
- RZLT $4.15
- CGEN $1.66
- Resistance Level
- RZLT $5.44
- CGEN $1.74
- Average True Range (ATR)
- RZLT 0.30
- CGEN 0.09
- MACD
- RZLT 0.05
- CGEN -0.02
- Stochastic Oscillator
- RZLT 75.00
- CGEN 14.41
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.